Clinical Trial Detail

NCT ID NCT02279719
Title A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Boston Biomedical, Inc
Indications

hepatocellular carcinoma

Therapies

Sorafenib

BBI503 + Sorafenib

Napabucasin + Sorafenib

Age Groups: adult

No variant requirements are available.